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Temozolomide (TMZ) is an oral alkylating agent used for the treatment of glioblastoma and
is now becoming a chemotherapeutic option in patients diagnosed with high-risk low-grade
gliomas. The O-6-methylguanine-DNA methyltransferase (MGMT) is responsible for the
direct repair of the main TMZ-induced toxic DNA adduct, the O6-Methylguanine lesion.
MGMT promoter hypermethylation is currently the only known biomarker for TMZ response
in glioblastoma patients. Here we show that a subset of recurrent gliomas carries MGMT
genomic rearrangements that lead to MGMT overexpression, independently from changes in
its promoter methylation. By leveraging the CRISPR/Cas9 technology we generated some of
these MGMT rearrangements in glioma cells and demonstrated that the MGMT genomic
rearrangements contribute to TMZ resistance both in vitro and in vivo. Lastly, we showed
that such fusions can be detected in tumor-derived exosomes and could potentially represent
an early detection marker of tumor recurrence in a subset of patients treated with TMZ.
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The therapeutic benefits of TMZ depend on its ability tomethylate DNA, which takes place at the N-7 and O6positions of guanine and N-3 position of adenine.
Although the minor product O6-methylguanine (O6-meG)
accounts for <10% of total alkylation, it exerts the greatest
potential for apoptosis induction1. O6-meG pairs with thymine as
opposed to cytosine during DNA replication. The O6-meG:thy-
mine mismatch can be recognized by the post-replication mis-
match repair (MMR) system and, according to the futile repair
hypothesis, ultimately induces DNA double-strand breaks, cell-
cycle arrest, and cell death2. The O6-methylguanine-DNA
methyltransferase (MGMT) is responsible for the direct repair
of O6-meG lesion by transferring the alkyl group from guanine to
a cysteine residue. Epigenetic silencing, due to promoter methy-
lation, of the MGMT gene prevents the synthesis of this enzyme,
and as a consequence increases the tumors sensitivity to the
cytotoxic effects induced by TMZ and other alkylating
compounds3,4. As today, MGMT promoter hypermethylation is
the only known biomarker for TMZ response4. However, the
discordance between promoter methylation and protein expres-
sion detected in a subset of patients limits the prognostic value of
methylation assessment5,6. Moreover, while MGMT methylation
at diagnosis predicts longer survival, this is not the case at
recurrence7. These evidence would suggest that other mechan-
isms, in addition to promoter methylation, could contribute to
MGMT upregulation in the recurrent tumors5,7.
According to the 2016 WHO classification, that integrates both
histological and molecular features, diffuse gliomas can be divided
in IDH-wildtype or IDH-mutant, by the presence of mutations in
the isocitrate dehydrogenase 1 and 2 (IDH1/2) genes8. TMZ is the
standard chemotherapeutic approach in IDH-wildtype gliomas,
such as glioblastomas, and, more recently in high-risk IDH-
mutant gliomas9.
By analyzing a large cohort of IDH-wildtype and mutant
recurrent gliomas treated with TMZ, we have discovered that a
subset of patients carries distinct MGMT genomic rearrange-
ments. These MGMT alterations lead to MGMT overexpression,
independently from changes in its promoter methylation, and
contribute to TMZ resistance both in vitro and in vivo.
Results
Identification of MGMT gene fusions in recurrent gliomas. To
reveal the landscape of TMZ resistance in glioma patients, we
analyzed RNA-sequencing data of 252 TMZ-treated recurrent
gliomas, among which 105 (42%) were newly collected (Supple-
mentary Fig. 1a, b and Supplementary Data 1). We then inte-
grated clinical information and performed bioinformatics analysis
to determine the mutational status of several key alterations
(“Methods”).
Overall, we found IDH1 mutation in 38.4% (94 out of 245)
patients, 1p/19q co-deletion in 9.4% (23 out of 245) patients,
MGMT promoter hypomethylation in 38% (52 out of 136)
patients, and DNA hypermutation in 10.7% (27 out of 252)
patients (Fig. 1a). By analyzing the RNA-seq data of 252 recurrent
gliomas, we identified eight different MGMT fusions in seven
patients (~3% of all patients, 95% CI, 1.1–5.6%) (Supplementary
Data 1 and Supplementary Table 1). Of note, among the seven
patients who harbor MGMT fusions, six are females, which is
significantly higher than expected (P= 0.015, Fisher exact test,
Supplementary Fig. 1c). Importantly, there was significant
mutual-exclusiveness between MGMT hypomethylation,
DNA hypermutation and MGMT fusion as revealed by a
bootstrapping method (P < 10−4, see “Methods”), suggesting
these alterations were carrying out alternative roles during cancer
progression.
Gliomas with MGMT fusions or hypomethylated MGMT
promoter had significantly higher MGMT expression, while the
DNA hypermutated patients showed the lowest MGMT expres-
sion, even lower than the MGMT-methylated tumors (Supple-
mentary Fig. 1d, P-values calculated by Wilcoxon rank-sum test).
Interestingly, we found that in IDH-wild-type glioma patients,
high MGMT expression indicates worse survival (P= 0.02, log-
rank test, Supplementary Fig. 1e), while it is associated to a trend
of better survival in IDH-mutant patients (P= 0.04, log-rank test,
Supplementary Fig. 1f). We next performed an in-depth
investigation of the eight different MGMT rearrangements:
BTRC-MGMT, CAPZB-MGMT, GLRX3-MGMT, NFYC-MGMT,
RPH3A-MGMT, and SAR1A-MGMT in HGG, and CTBP2-
MGMT and FAM175B-MGMT in LGG (Fig. 1b). Five of the
eight partner genes located on chromosome 10q, mostly close to
MGMT (Fig. 1b). Interestingly, although the left partners of the
MGMT fusions were different, the transcriptomic breakpoint in
MGMT invariably located at the boundary of MGMT exon 2,
which is 12 bp upstream of the MGMT start codon. In three of
the rearrangements (SAR1A-MGMT, RPH3A-MGMT, and
CTBP2-MGMT), MGMT coding sequence was fused to the 5′
UTR of the fusion partner. Reconstruction of the chimeric
transcripts found all fusions are in-frame, and both the
methyltransferase domain and DNA-binding domain of MGMT
are intact, suggesting the functions of MGMT might be preserved
in the fusion proteins (Fig. 1c). We validated the gene fusions
using PCR and Sanger sequencing in samples with enough
specimen available (Fig. 1d, e). For one patient (CGGA_1729), we
performed whole-genome sequencing (WGS), and analysis of
structural rearrangements in this sample revealed a deletion of
about 4.8 Mb resulting in the FAM175B-MGMT fusion (Fig. 1f).
MGMT genomic rearrangements lead to MGMT overexpression.
To characterize the MGMT fusions, we sought to generate some of
the identified rearrangements using the CRISPR/Cas9-mediated
genome editing. Co-expression of Cas9 with pairs of single-guide
RNAs (sgRNAs) has been used to model a variety of chromosomal
rearrangements (such as translocations, inversions, and deletions)
by creating DNA double-strand breaks at the breakpoints of
chromosome rearrangements, which are then joined by non-
homologous end joining10,11. To generate cell lines carrying the
MGMT fusions, we first transduced U251 and U87 cells, two
MGMT-methylated GBM cell lines, with lentiviral vectors
expressing different combinations of gRNA pairs directed to four
different MGMT rearrangements: BTRC-MGMT, NFYC-MGMT,
SAR1A-MGMT, and CTBP2-MGMT (Supplementary Fig. 2a–c).
The expected chromosomal rearrangements in the bulk popula-
tions were detected by PCR at the genomic level and confirmed by
Sanger sequencing (Supplementary Fig. 3a, b). The newly gener-
ated cell populations were then exposed to TMZ. Surviving clones
were observed only in the bulk populations of cells carrying the
different fusion events but not in the control cells (sgCtrl, non-
targeting sgRNA) (Fig. 2a). We then isolated some of the TMZ-
resistance clones and further confirmed the presence of the desired
gene fusion by PCR both at the genomic level (Supplementary
Fig. 3c) and at mRNA level by reverse transcription PCR (RT-
PCR) of cDNA fragments overlapping the fusion exon junctions
(Supplementary Figs. 3d–f and 6a). However, we could not con-
firm at the genomic level the exact breakpoints in the CTBP2-
MGMT clones, both in U251 and U87 cells, possibly to the
occurrence of larger deletions that removed the binding site of the
primers used for our initial studies in the bulk population (Sup-
plementary Fig. 3a, b). Nevertheless, the desired genomic rear-
rangements were further validated using a break-apart fluorescence
in situ hybridization (FISH) assay (Supplementary Fig. 4).
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-17717-0
2 NATURE COMMUNICATIONS |         (2020) 11:3883 | https://doi.org/10.1038/s41467-020-17717-0 | www.nature.com/naturecommunications
Promoter exchanges are one class of gene fusions, character-
ized by the replacement of a gene’s regulatory regions with those
of another gene, often resulting in deregulation of transcription of
the genes participating in the fusion event12–14. Another class of
gene fusions generates chimeric proteins with biological function
different from either of the partner genes from which it
originated12–14. Since all the MGMT gene fusions identified had
similar structures, with the 5′ gene contributing with either small
and diverse protein domains or just with the 5′-UTR regions
(Fig. 1c), we hypothesized that the TMZ resistance might be
driven by increased MGMT expression due to the rearrangements
that bring the MGMT gene under the control of a more active
promoter. Real-time quantitative PCR showed a striking increase
of MGMT expression in the clones carrying the different fusions
(Fig. 2b), as compared with control cells, without changes in
MGMT promoter methylation status, as evidenced by
methylation-specific PCR (MSP) (Fig. 2c). These results are in
line with what observed in the patient cohort: patients carrying
MGMT rearrangements showed elevated expression of MGMT,
concurrently with a methylated MGMT promoter (Fig. 1a;
Supplementary Fig. 1d). Western blot analysis, using an anti-
MGMT antibody, evidenced a marked overexpression of MGMT
at the protein level, especially obvious for the SAR1A-MGMT and
CTBP2-MGMT fusion clones (Fig. 2d). Moreover, we observed
higher-molecular-weight protein products for BTRC-MGMT and
NFYC-MGMT, consistent with the expected size of those fusion
proteins. Of note, the different levels of MGMT expression might
be determined by the activity of the specific gene’s promoter
participating in the fusion event and/or by the number of copies
of the genomic rearrangement in each specific clone.
To validate our results in an another biologically relevant
model of GBM, we also used patient-derived cell line propagated
in stem cell medium. These cells, as compared with immortalized

































CAPZB-MGMT Methyltransferase DNA binding
1 24 235
FAM175B-MGMT Methyltransferase DNA binding
1 67 278









































Fig. 1 Multiple MGMT fusions in TMZ-treated recurrent gliomas. a Landscape of MGMT hypomethylation, MGMT fusions, DNA hypermutation. b Circos
plot showing the identifiedMGMT fusions. c Structure of the MGMT fusion proteins. Each partner gene is indicated by color, and the narrow bars in SAR1A-
MGMT, RPH3A-MGMT, and CTBP2-MGMT mean 5′UTR. d, e Validation of the MGMT fusion genes in positive samples by PCR and Sanger sequencing.
The bands in the left panel were validated by Sanger sequencing in the right panel. Limited by specimen availability the validation was performed once.
f The genomic rearrangement generating FAM175B-MGMT fusion. WGS whole-genome sequencing. Source data are provided as a Source Data file.
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genotype, phenotype, as well as heterogeneity of the original
tumor both in vitro and in vivo. We generated and confirmed at
genomic and mRNA levels the BTRC-MGMT and SAR1A-
MGMT fusion events in the MGMT-negative patient-derived
h543 GBM tumor spheres (Supplementary Fig. 7a–c). Similar to
what observed for U251 and U87, h543 cells carrying the fusions
showed increased expression of MGMT at mRNA and protein
level, as compared with control cells (Supplementary Fig. 7d, e).
MGMT gene fusions contribute to TMZ resistance. To establish
whether the TMZ resistance in the clones carrying the fusions was
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Fig. 2 MGMT fusions cells show enhanced TMZ resistance via increased MGMT expression. a Colony-forming assay performed on U251 and U87 cells
expressing sgCtrl, BTRC-MGMT, NFYC-MGMT, SAR1A-MGMT, CTBP2-MGMT exposed for 12 days to TMZ (100 μM) or DMSO. b MGMT quantitative-
PCRs performed on mRNA from U251 and U87 TMZ-resistant single-cell clones expressing the indicated MGMT fusions. Data are from a representative
experiment of n= 3 biological replicate. Centre of the bars represent the mean (technical replicate n= 3) and the error bars are the standard deviations.
c Analysis of MGMT promoter methylation, by methylation-specific PCR (MSP), in the TMZ-resistant cell clones expressing the indicated MGMT fusions
from U251 (left panel) and U87 (right panel). M and U lanes indicate methylated and unmethylated status of the promoter, respectively. LN18 and U87
cells are shown as control for unmethylated and methylated, respectively. d Western blot analysis of MGMT protein levels in TMZ-resistant cell clones
from U251 and U87 expressing the indicated MGMT fusions. Source data are provided as a Source Data file.
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protein, and not caused by other mutations acquired during TMZ
treatment, we analyzed the TMZ sensitivity in presence of O6-
benzylguanine (O6-BG), a synthetic derivative of guanine that
inhibit MGMT activity15. Clonogenic assay of two independent
U251 clones per fusion showed that the TMZ sensitivity was re-
established by the co-treatment with O6-BG (Fig. 3a). By contrast,
cell knockout for the mismatch repair gene MSH6, a proposed
TMZ-resistance mechanism independent from MGMT expres-
sion, was fully TMZ-resistant also in the presence of O6-BG.
Similarly, cell-cycle profile analysis with propidium iodide staining
and EdU incorporation assays showed that the fusion clones
bypassed the TMZ-induced accumulation in the G2/M phase and
O6-BG co-treatment was able to re-establish the cell-cycle arrest
(Fig. 3b-d). We noticed that individual clones showed variable
TMZ sensitivity when treated concurrently with O6-BG. Clones
with higher MGMT expression (e.g., NFYC-MGMT clone 2 and
SAR1A-MGMT clones) showed increased resistance to TMZ;
however, in these cells increasing doses of O6-BG significantly
enhanced TMZ cytotoxic effect (Supplementary Fig. 5a, b). Same
results were obtained in U87 fusion clones (Supplementary
Fig. 6b, c) and in h543 tumor spheres (Supplementary Fig. 7f, g).
We then assessed to which extent the TMZ resistance was
determined by increased MGMT activity, and therefore boosted
by the DNA repair potential of the fusion clones. Quantitative
high-throughput microscopy analysis revealed that in MGMT
fusion expressing cells, similarly to what observed in sgRNA
MSH6 cells, TMZ treatment did not increase levels of γH2AX and















































































































































































































































































































































Fig. 3 MGMT fusions protect from TMZ-induced damage. a Clonogenic survival assay of U251 clones expressing MGMT fusions exposed to O6-BG
(100 μM) or/and TMZ (100 μM) for 12 days. U251sgMSH6 cells are shown as control for TMZ resistance independently from MGMT. b Cell-cycle
distribution of U251 MGMT fusion expressing cells in presence of O6-BG (100 μM) or/and TMZ (100 μM) for 72 h, measured by propidium iodide (PI)
staining and FACS. U251 sgCtrl and sgMSH6 are shown as control. c High-throughput microscopy-mediated quantification of cell-cycle distribution at 48 h
after treatment. See “Methods” for details. d Quantification of the percentage of cells in c. Data are from a representative experiment repeated in triplicate
and presented as mean (technical replicate n= 3) and standard deviation. e, f High-throughput microscopy-mediated quantification of γH2AX intensity
levels and 53BP1 foci in U251 cells expressing theMGMT fusions after 48 h of treatment with 100 μM of the indicated drugs. U251 sgCtrl and sgMSH6 were
included as controls. The bottom and top of each box represents the first and third quartiles, and the line inside is the median. The whiskers correspond to
1.5 times the interquartile range. Data are representative of n= 3 biologically independent experiments. Two-sided Student’s t test with Bonferroni
adjustment for multiple comparisons: ***P < 0.001, **P < 0.01, *P < 0.05, ns not significant, A.U. arbitrary unit. Source data are provided as a Source
Data file.
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DNA double-strand breaks (Fig. 3e, f). However, MGMT
inhibition by O6-BG led to the accumulation of γH2AX and
53BP1 foci upon TMZ treatment in the fusion clones. Taken
together, these data indicate that TMZ resistance induced by
MGMT genomic rearrangements is mechanistically linked to
MGMT activity.
MGMT gene fusions protect from TMZ treatment in vivo.
Lastly, we evaluated the TMZ resistance of MGMT fusion in vivo
through establishing nu/nu mice xenograft models with the U251
BTRC-MGMT and control cells, previously transduced with a
luciferase expressing construct. A week after intracranial trans-
plantation, mice were intraperitoneally treated with TMZ (50 mg/
Kg) or DMSO (0.3%) for 5 days, and tumor growth was mon-
itored weekly with bioluminescence imaging (BLI) for 4 weeks.
Mice with MGMT fusion-bearing tumors exhibited no significant
prolonged lifespan between TMZ and DMSO group, and sig-
nificantly poorer survival compared with control mice when
receiving TMZ treatment (Fig. 4a). Similarly, while TMZ treat-
ment significantly extended the survival of mice transplanted with
h543 transduced with the sgCtrl, it failed to do so in those
expressing the SAR1A-MGMT rearrangement (Supplementary
Fig. 7h). BLI analysis confirmed that TMZ antitumor effect was
limited to control mice (Fig. 4b). In addition, as shown by
immunohistochemistry, the BTRC-MGMT mice had increased
BrdU incorporation and reduced accumulation of γH2AX
compared with control mice upon TMZ administration (Fig. 4c),
confirming our proliferation and DNA repair in vitro results.
In clinical settings, liquid biopsies can be a powerful
noninvasive technique to monitor cancer-associated genetic
alterations by analyzing circulating tumor cells (CTCs), circulat-
ing free DNA (cfDNA) or tumor-derived extracellular vesicle
(EV), including exosomes (EXOs). Previous studies have already
showed that (i) glioma-derived extracellular vesicle (EV) can
cross the blood brain barrier and be detected in peripheral blood
of patients16, (ii) MGMT mRNA is enriched in glioma exosomes
(EXOs)17, and (iii) other gene fusion was identified in glioma
EXOs18. Based on these findings, we assessed whether theMGMT
fusions could be detected in EXOs. We purified EXOs from
conditioned media of cells harboring SAR1A-MGMT and sgCtrl
by standard ultracentrifugation. Western blot of protein content
confirmed enrichment in the EXOs of the exosome-specific
markers TSG101 and Alix (Fig. 4d) and the presence of MGMT
in the cells expressing the fusion event (Fig. 4d). Most
importantly, also the mRNA of the MGMT fusion was detected
by RT-PCR in the EXOs (Fig. 4e).
Lastly, to further evaluate a clinical application of our
findings, we tested whether EXOs isolated from blood serum
of mice injected orthotopically with the U251 BTRC-MGMT
cells would also exhibit the fusion transcript. Remarkably, RT-
PCR analysis confirmed the presence of the cDNA fusion
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Fig. 4 MGMT fusions confer TMZ resistance in vivo and serve as biomarkers at recurrence. a Top panel: scheme of the in vivo experimental design.
Bottom panel: Kaplan–Meier survival curve of animals intracranially injected with U251 sgCtrl and U251 BTRC-MGMT clone 2 cells transduced with a
luciferase construct, treated or not with TMZ (50mg/Kg) for 5 days: sgCtrl Vehicle n= 4, sgCtrl TMZ n= 5, BTRC-MGMT vehicle n= 4, BTRC-MGMT
TMZ n= 5. sgCtrl log-rank P-value= 0.0049, BTRC-MGMT log-rank P-value= 0.9273. b Representative luminescent images of the tumor bearing at the
indicated time points. c Immunohistochemistry analysis against BrdU and γH2AX of tumors from mice injected with U251 sgCtrl and BTRC-MGMT clone 2
cells, treated or not with TMZ (50mg/kg) for 3 days. Mice were sacrificed 2 h after BrdU injection. Scale bars: 100 μm. dWestern blot analysis of the EXO
markers Alix and TSG101 and of MGMT levels in samples pair of cells and cell-derived EXOs expressing sgCtrl and SAR1A-MGMT. e SAR1A-MGMT and
MGMT mRNA expression by RT-PCR in RNA pair samples from cells and cell-derived EXOs expressing sgCtrl and SAR1A-MGMT. f Transcript levels of
BTRC-MGMT by RT-PCR analysis in EXOs isolated from serum of BTRC-MGMT clone 2 tumor-bearing mice compared to sgCtrl mice. U251 sgCtrl and
BTRC-MGMT clone 2 cells were included as controls. Source data are provided as a Source Data file.
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Discussion
Currently, TMZ is the only chemotherapeutic drug that is
established to considerably extend the overall survival of GBM
patients and is becoming a therapeutic option also for high-risk
low-grade gliomas9. Both intrinsic and acquired resistance
might contribute to glioma tumor recurrence upon TMZ
treatment. While MGMT promoter hypomethylation is
undoubtedly recognized as the primary mechanism of intrinsic
TMZ resistance, the genetic alterations acquired during TMZ
exposure that contribute to tumor relapse still remain to be
fully characterized.
Defects in various components of the MMR machinery pos-
sibly represent one of the most well-characterized mechanism of
acquired TMZ resistance. Though rarely detected in primary
GBMs, MMR alterations have been previously described in
10–20% of recurrent tumors7,19,20. Changes in MGMT promoter
methylation status during tumor progression have been observed
only in a small subset of patients19. More recently, it has also been
suggested that in recurrent GBMs enhancer hijacking could
promote MGMT expression, despite promoter methylation, and
therefore TMZ resistance; however, the clinical significance of
these findings still remain to be evaluated5.
In this study, we demonstrated that MGMT fusions repre-
sent a previously unidentified genetic alteration that contribute
to MGMT overexpression and a novel mechanism of acquired
TMZ resistance that is mutually exclusive from MGMT pro-
moter hypomethylation and the hypermutator phenotype,
typically associated with MMR defects. For those patients for
whom both primary and recurrent tumor were available (4 out
of 7), the MGMT rearrangements were detected only in the
tumor relapse. Although we cannot exclude that some of the
primary tumors might express the MGMT fusion at subclonal
level, and therefore possibly lower than the RNA-seq detection
limits, we speculate that the MGMT rearrangements have been
acquired during the course of TMZ treatment and then posi-
tively selected due to their ability of driving TMZ resistance.
Very recently, another MGMT gene fusion, ASAP2-MGMT,
with similar features to the fusions that we have described here
in gliomas, has been identified in a medulloblastoma patient
that relapsed after TMZ treatment21. These data would suggest
that MGMT genomic rearrangements could represent a rele-
vant mechanism of resistance to alkylating agents across a
broader spectrum of tumor types.
Although the presence of the MGMT gene fusions in
extracellular vesicles appears to be promising as a possible
liquid biopsy approach for the identification of MGMT rear-
rangements, its validity still remains to be validated in the
clinical settings. Early detection of MGMT genetic rearrange-
ments in patients under treatment would eventually predict
early tumor recurrence and guide therapy decision in a subset
of MGMT-methylated patients. Unlike primary tumors, at the
time of recurrence there is not a standard of care available for
gliomas, and TMZ rechallenge is one of the few options in
glioblastomas22. MGMT promoter methylation has been pro-
posed as prognostic marker for benefit from TMZ rechallenge
in recurrent glioblastoma23 and is used as a stratification factor
in trials comprising TMZ treatment24. However, our current
findings might limit MGMT promoter methylation prognostic
value and would predict that a subset of patients might be
assigned to the wrong treatment arm, if based solely on MGMT
promoter methylation analysis.
In summary, here we have presented MGMT genomic rear-
rangements not only as a novel mechanism of resistance to TMZ
in a subset of gliomas but also, to our knowledge, as a unique
genetic alteration never described before in response to other
chemotherapeutic agents.
Methods
Patients. The newly sequenced tumors were collected from Beijing Tiantan
Hospital as part of the Chinese Glioma Genome Atlas project (CGGA, http://cgga.
org.cn/). The study was approved by the institutional review board in Capital
Medical University (IRB ID: KYSB2015-023). Informed consent was obtained from
each patient before surgery. For each specimen, the pathological diagnosis was
reviewed by board-certificated pathologists. The specimen was flash-frozen within
5 min after being resected for subsequent RNA extraction and sequencing.
We also curated RNA sequencing from four published studies. This include
72 samples from Wang et al.7, 42 samples from Hu et al.25, 28 samples from Bao
et al.26, and 5 samples from The Cancer Genome Atlas27 (Supplementary Fig. 1 and
Supplementary Data 1).
The most recent follow-up information of the TCGA patients were retrieved
from NCI Genomics Data Commons (GDC) data portal (https://portal.gdc.cancer.
gov, accessed on July 18, 2019). Similarly, we used the most recent follow-up
information (last follow-up in December 2018) of all patients from CGGA. For the
41 patients from Samsung Medical Center (SMC), patient follow-up continued
after the publication of our last study7, and the updated data were used in this
study. In total, 12 out of 41 patients changed survival status and/or surviving time.
In addition, the MGMT methylation status of the recurrent gliomas from seven
patients were newly tested and updated in this study.
RNA sequencing and gene expression quantification. RNA-sequencing assay of
the newly collected glioma samples in this study was performed using the same
protocol as our previous research28. For each sample, about 80 million reads were
generated.
The cleaned RNA-sequencing reads were mapped to the reference human
genome assembly of Ensembl GRCh37 annotation version 75 using STAR 2.6.1d29
with default parameters. Reads mapped to each gene were counted using
FeatureCount 1.5.130 and transformed to RPKM. Since our cohort includes
samples from multiple cohorts, we used Z-score of MGMT expression in the
recurrent glioma samples within each cohort for normalization to overcome
potential batch effects.
Detection of MGMT fusion from RNA-sequencing data. RNA-sequencing data
from previous publications were downloaded, and the reads were extracted using
samtools 1.231. STAR-fusion 1.5.032 was utilized to identify and annotate gene
fusion candidates, using the fastq files as input. The fusion candidates were then
filtered by removing fusions that were present in normal tissues, fusions involving
mitochondria genes and uncharacterized genes, and fusions of two paralog genes.
See Supplementary Table 1 for the breakpoint information of the MGMT fusions
identified.
Whole-genome sequencing and analysis. For one MGMT fusion positive case
(CGGA_1729), we had enough sample for whole-genome sequencing. The total
DNA was extracted and sequenced using Illumina HiSeq 4000 platform. The
sequencing depth is about 50×. Sequencing reads were then cleaned and mapped to
hg19 reference genome using bwa mem 0.7.15-r114033. Duplicates were marked
using Picard MarkDuplicates 2.9.2 tool (https://broadinstitute.github.io/picard/).
Structural variants were identified using Manta 1.4.034, and the variant related to
the MGMT fusion was manually picked.
Determination of IDH, 1p/19q co-deletion, and hypermutation. The mutation
status of IDH1 Arginine 132 and IDH2 Arginine 172 were determined from RNA-
seq data using samtools 1.2 mpileup. At least five reads were required to cover the
hotspot position, otherwise the result was marked as not available (NA).
The 1p/19q co-deletion status was predicted using CNAPE35. CNAPE is a
software to predict large-scale copy number alteration from gene expression data
using multinomial logistic regression models trained on TCGA data and have
shown high sensitivity and specificity. The 1p/19q co-deletion prediction results
were further confirmed by the allele frequency of common SNPs. Hypermutation
was identified using a computational method based on RNA-sequencing data36.
A bootstrapping method to test mutual-exclusiveness. To test whether the
three TMZ-resistance-related alterations, namely MGMT promoter hypomethyla-
tion, hypermutation, andMGMT fusion, are mutually exclusive, we reasoned that if
they are mutual exclusive, then when combined they should cover significantly
more patients than random. Note the contraposition also holds. We therefore
randomly assigned the patients whether they had the alteration and summarized
the number patients that had at least one of the three alterations. This randomized
assignment was repeated for 10,000 times. P-value was calculated by (times for
which the number of covered patients is larger than the observed number of
patients carrying at least one such alteration)/10,000.
PCR validation of MGMT fusion in patient samples. The total RNA was
extracted from the positive fusion glioma samples using RNeasy Mini Kit (Qiagen)
according to the manufacturer’s instructions, and RNA intensity was examined by
Bioanalyzer 2100 (Agilent Technologies). Then cDNA was synthesized from 1 μg of
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the total RNA using the RevertAid First Strand cDNA Synthesis kit (Thermo Fisher
Scientific, Cat. K1622), with random hexamer as the primer. The MGMT fusion
gene fragments were amplified by PCR using specific primers (Supplementary
Table 2). The PCR products were purified using a QIAquick PCR purification kit
(Qiagen, Cat. 28104) and sequenced by an ABI Prism 3730 DNA sequencer
(Applied Biosystems).
DNA constructs, design, and cloning of guide RNAs. The pKLV-U6gRNA-
PGKpuro2ABFP (Plasmid #50946) and the lentiCas9-Blast (Plasmid #52962) were
obtained from Addgene. The HSV1-tk/GFP/firefly luciferase (TGL) triple-reporter
construct was from J. Gelovani Tjuvajev37. The gRNA sequences targeting MGMT,
BTRC, NFYC, SAR1A, and CTBP2 were designed using the Genetic Perturbation
Platform web portal (http://portals.broadinstitute.org/gpp/public/analysis-tools/
gRNA-design) (Supplementary Table 3). The paired sgRNAs were sub-cloned into
the pKLV-U6gRNA-PGKpuro2ABFP, as previously described11. Briefly, the oli-
gonucleotides containing the different gRNA pairs (Supplementary Table 4) were
amplified with Phusion High-Fidelity polymerase (New England Biolabs, M0530S)
using primer F5 and R1 (Supplementary Table 2). PCR products were gel-purified
and ligated to BbsI-digested pDonor_mU6 plasmid (kindly provided by A. Ven-
tura) by using the Gibson Assembly Master Mix (New England Biolabs
174E2611S). The Gibson reaction was then digested with BbsI at 37 °C for 3 h. The
linearized fragment containing the pair gRNA, the mU6 promoter, and the gRNA
scaffold was gel-purified and cloned into the pKLV-U6gRNA-PGKpuro2ABFP. All
the constructs were verified by Sanger sequencing.
Cell lines, transfections, infections, and reagents. The human glioma cell lines
U251 (Sigma-Aldrich, 09063001) was kindly provided by Eric Holland, and U87
(HTB-14) was purchased from ATCC. The Gp2-293 packaging cell line was pur-
chased from Clontech (Cat. 631458). Cells were cultured in DMEM (Sigma-
Aldrich, Cat. D5796)+ 10% FBS (Sigma-Aldrich, Cat. F7524). All the cell lines
were routinely checked for Mycoplasma contamination by PCR analysis. DNA
fingerprinting has been performed for authentication of the U251 and U87 cell
lines (data available upon request). Human GBM tumor spheres h543, kindly
provided by Eric Holland, were cultured in human NeuroCult NS-A Proliferation
Kit (Stem Cell Technologies, Cat. 05751) and supplemented with 10 ng/ml
recombinant human EGF (Gibco, Cat. PHG0313), 20 ng/ml basic-FGF (Sigma-
Aldrich, Cat. F0291-25UG), 1 mg/ml heparin (Stem Cell Technologies, Cat. 07980),
100 U/ml penicillin, and 100 µg/ml streptomycin.
Lentiviruses were generated by co-transfection of lentiviral plasmids (pKLV-
U6gRNA-PGKpuro2ABFP and lentiCas9-Blast) and 2nd generation packaging
vectors (pMD2G and psPAX2) in Gp2-293 cells using calcium–phosphate
precipitate. High-titer virus was collected at 36 and 60 h following transfection, and
used to infect cells in presence of 7 μg/ml polybrene (Sigma-Aldrich, Cat. H9268-
5G) for 12 h. Transduced cells were selected with Blasticidin (3 μg/ml) (Gibco, Cat.
A11139-03) and Puromycin (1.5 μg/ml) (Sigma-Aldrich, Cat. P8833-25MG). To
isolate clones of U251 and U87 cells carrying the desired MGMT genomic
rearrangements, after transduction with the specific pKLV-dual gRNA vectors, the
cells were selected with Puromycin and then exposed to Temozolomide. Single
TMZ-resistance clones were then recovered with cloning cylinders and then
expanded.
Temozolomide was purchased from Selleckchem (Cat. S1237). O6-
benzylguanine was from Sigma-Aldrich (Cat. B2292-50MG).
Immunoblotting. Cells were lysed with RIPA lysis buffer (20mM Tris-HCl, 150mM
NaCl, 1% NP-40, 1 mM EDTA, 1 mM EGTA, 1% sodium deoxycholate, 0.1% SDS),
and protein concentrations were determined by DC protein assay kit (Biorad, Cat.
5000111). Proteins were run on house-made SDS-PAGE gels and transferred to the
nitrocellulose membrane (Amersham, Cat. GEHE10600003). Membranes were first
incubated in blocking buffer (5% milk 0.1% Tween, 10 mM Tris at pH 7.6, 100 mM
NaCl) and then with primary antibody MGMT (Biosciences, Cat. 557045, Lot.
6280927, 1:2000), Alix (Cell Signaling, Cat. 2171, Lot. 5, 1:1000), TSG101 (BD
Transduction Laboratories, Cat. 612696, Lot. 7208980, 1:2000) overnight at 4 °C,
p85 (Millipore, Cat. 0619, Lot. 3009962, 1:10,000), GAPDH (Santa Cruz, Cat. Sc-
365062, Lot. J1314, 1:500), and Vinculin (Sigma-Aldrich, Cat. V9131, 1:10.000) for
1 h at room temperature. Anti-mouse or rabbit-HRP conjugated antibodies
(Jackson Immunoresearch) were used to detect desired protein by chemilumines-
cence with ECL (Amersham, RPN2106).
Immunohistochemistry. Tissue samples were fixed in 10% formalin, paraffin-
embedded and cut in 3-μm sections, which were mounted in superfrostplus
microscope slides (Thermo Scientific, Cat. 165061) and dried. The immunohis-
tochemistry was performed using an automated immunostaining platform (Ven-
tana discovery XT, Bond Max II, Leica). Antigen retrieval was performed with low
pH buffer (CC1m) for p-H2AX and high pH buffer (ER2) for BrdU. Endogenous
peroxidase was blocked (peroxide hydrogen at 3%), and slides were then incubated
with anti-BrdU (BU-1, GE Healthcare, RPN202, Lot. 341585, 1:100) and phospho-
histone H2AX (Ser139) (γH2AX, JBW301, Millipore, 05-636, Lot. DAM1493341,
1:4000). After the primary antibody, slides were incubated with the corresponding
secondary antibodies when needed (rabbit anti-mouse Abcam) and visualization
systems (Omni Map anti-Rabbit, Ventana, Roche; Bond Polymer Refine Detection,
Bond, Leica) conjugated with horseradish peroxidase. Immunohistochemical
reaction was developed using 3,30- diaminobenzidine tetrahydrochloride (DAB)
(ChromoMap DAB, Ventana, Roche; Bond Polymer Refine Detection, Bond,
Leica), and nuclei were counterstained with Carazzi’s hematoxylin. Finally, the
slides were dehydrated, cleared, and mounted with a permanent mounting medium
for microscopic evaluation.
Colony-forming assay. Cells were seeded in six-well culture plates (5000 per well)
or in 12-well plates (2200 per well) in triplicate. After 4 h from the seeding,
Temozolomide (100 or 200 μM) and/or O6-benzylguanine (100 μM) were added to
the cells, and fresh media with drugs was replaced after 6 days. Twelve days after
plating, resistant colonies were either stained with 0.5 M of crystal violet (Alfa
Aesar, Cat. B21932) or isolated using cloning cylinders (Corning, Cat. 31666) and
subsequently amplified.
Flow cytometry. Cells were seeded in six-well culture plates (100,000 per well) in
duplicates and cultured in presence of temozolomide (100 μM) and/or O6-benzyl-
guanine (100 μM) for 72 h. Cells were then harvested by phosphate-buffered saline
(PBS), washed twice in cold PBS, fixed with cold 100% ethanol on ice for 30 min,
and pelleted by centrifugation at 1200 rpm for 10min. Pellet was then washed twice
with PBS and 1% fetal bovine serum (FBS) and stained with 200 μl of propidium
iodide (PI) (50 μg/ml) overnight. Samples were acquired on a FACS Canto II
(Beckton Dickinson). All data were analyzed using FlowJo 9.9.4 (Treestar, Oregon).
Gating strategy is described in Supplementary Fig. 8.
MTT assays. For viability assays, 104 tumor spheres h543 were plated per well in
96-well plates. After addition of the indicated concentrations of temozolomide or
vehicle, cells were incubated for 7 days at 37 °C and 5% CO2. In total, 10 μl of MTT
reagent (Sigma, 5 mg/ml in PBS) were then added to the media and incubated for
4 h. After adding 100 µl of a 1% SDS, 4 mM HCl solution, absorbance at 595 nm
was recorded after 24 h with a plate reader.
High-throughput microscopy. Cells (2000 per well) were grown on a μCLEAR
bottom 96-well plates (Greiner Bio-One, Cat. 736-0230) and treated with temo-
zolomide (100 μM) and/or O6-benzylguanine (100 μM) in triplicates for 48 h. EdU
(10 μM) (Life Technologies, S.A., Cat. A10044) was added to the media at the last
hour of incubation with the drugs. Cells were then fixed in 4% PFA for 20 min,
permeabilized, and incubated for 1 h in blocking solution (3% BSA in 0.1% Triton-
X PBS). EdU incorporation was detected using the Click-iT™ EdU Alexa Fluor®
Imaging kit (Life Technology, S.A., Cat. C-10425). Phospho-histone H2AX
(Ser139) (γH2AX, Merck, Cat. 05-363, Lot. 2310355, 1:1000) and 53BP1 (Novus
Biologicals, Cat. NB100-304, Lot. A2, 1:3000) immunofluorescence was performed
using standard procedures. Cells were incubated with primary antibodies overnight
at 4 °C, and secondary antibodies conjugated with Alexa 488 (rabbit) (Life Tech-
nologies, Cat. A-21206, Lot. 198155, 1:400) or Alexa 555 (mouse) (Life Technol-
ogies, Cat. A-31570, Lot. 1048568, 1:400). Nuclei were visualized by DAPI staining
(Sigma-Aldrich, Cat. D8417). Images from each well were automatically acquired
by an Opera High-Content Screening System (Perkin Elmer) at non-saturating
conditions with a ×20 (γH2AX) and ×40 (53BP1) magnification lens. Images were
segmented using the DAPI staining to generate masks matching cell nuclei from
which the mean signals were calculated. Cell-cycle phases were inferred based on
DNA content (DAPI intensity*nuclear area) and EdU mean intensity: cells with 2n
DNA content and EdU-negative were considered as G1 phase; <4n DNA content
and EdU-positive, as S phase; 4n DNA content and EdU low or negative, as
G2 phase.
Genomic DNA isolation, gene fusion analysis, and methylation-specific PCR.
Genomic DNA was isolated as previously described11. Briefly, cell pellets were
incubated in lysis buffer (10 mM Tris-HCl ph8, 100 mM NaCl, 0.5 mM EDTA,
10% SDS, and proteinase K) for 4 h at 55 °C, and genomic DNA was extracted
using phenol:chloroform (1:1) and Phase Lock heavy 2-ml tubes (5PRIME, Cat.
2302830). In all, 0.1 M sodium acetate and 100% cold ethanol were then added to
the recovered aqueous phase. Samples were centrifuged at 15,000 rpm for 25 min.
After washing in 70% cold ethanol, draining, and dissolving in water, genomic
DNA was quantified.
For detection of gene fusion events, 100 ng of DNA were amplified with specific
primers listed in (Supplementary Table 2). PCR products were cloned into the
pGEM-T Easy vector (Promega, Cat. A1360) and submitted to Sanger sequencing.
The MGMT promoter methylation status was determined by methylation-
specific PCR (MSP). In total, 2 μg of DNA were subjected to bisulfite treatment
using the EpiTect® Bisulfite kit (Quiagen, Cat. 59104). DNA was cleaned up
following the manufacturer’s instructions and quantified. In all, 30 ng of DNA per
sample were PCR-amplified with the Platinum SuperFi DNA polymerase
(Invitrogen, Cat. 12351-010) and specific primers to detect methylated and
unmethylated MGMT promoter (Supplementary Table 2). The PCR amplification
protocol was as follows: 94 °C for 1 min, then denature at 94 °C for 30 s, anneal at
60 °C for 30 s, extension at 70 °C for 30 s for 35 cycles, followed by a 7-min final
extension.
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Reverse transcription quantitative PCR and analysis of cDNA fragments. RNA
from cells was isolated with TRIzol reagent (Invitrogen, Cat. 15596-026) according
to the manufacturer’s instructions. For reverse transcription PCR (RT-PCR), 500
ng of the total RNA was reverse transcribed using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems, Cat. 4368814). The cDNA was
used either for quantitative PCR or Sanger sequencing. The cDNA was PCR-
amplified using primers listed in Supplementary Table 2, in-gel-purified and ligated
into the pGEM-T Easy vector (Promega, Cat. A1360) and submitted to Sanger
sequencing. Quantitative PCR was performed using the SYBR-Select Master Mix
(Applied Biosystems, Cat. 4472908) according to the manufacturer’s instructions.
qPCRs were run, and the melting curves of the amplified products were used to
determine the specificity of the amplification. The threshold cycle number for the
genes analyzed was normalized to ACTIN. Sequences of the primers used are listed
in Supplementary Table 2.
Fluorescence in situ hybridization (FISH). Two sets of FISH probes were used to
study the various MGMT genomic rearrangements. Bacterial artificial chromo-
somes (BACs) that map at the 5′ and 3′ MGMT flanking regions (10q26 cytoband)
were purchased from BACPAC Resoirce CHORI and labeled by Nick translation
assay with Spectrum Green (RP11-165L12 and RP11-343L20) and Spectrum
Orange (RP11-960B17 and RP11-357N5) fluorochromes, respectively, to generate a
break-apart locus-specific FISH probe. FISH analyses were performed according to
the manufacturers’ instructions, on Carnoy’s fixed cells mounted on positively
charged slides (SuperFrost, Thermo Scientific). Briefly, the slides were first dehy-
drated followed by a denaturing step in the presence of the FISH probe at 85 °C for
10 min and left overnight for hybridization at 45 °C in a DAKO hybridizer
machine. Finally, the slides were washed with 20 × SSC (saline-sodium citrate)
buffer with detergent Tween-20 at 63 °C, and mounted in fluorescence mounting
medium (DAPI). FISH signals were manually enumerated within nuclei. FISH
images were also captured using a CCD camera (Photometrics SenSys camera)
connected to a PC running the CytoVision Version 7.4 image analysis system
(Applied Imaging Ltd., UK).
Exosomes isolation. To purify exosomes from cell culture, the conditioned media
was collected after 72 h from 10 × 15 cm plates and centrifuged at 500 × g for 10min
followed by centrifugation at 12,500 × g for 25min and 100,000 × g for 80min. The
exosome pellet was then washed with cold PBS, centrifuged at 100,000 × g for 80min
and re-suspended in 100 μl PBS. Isolation of exosomes from mice serum was per-
formed following the same protocol after an initial centrifugation at 3000 × g for 20
min and a further one at 12,000 for 20min. NanoSight analysis was used to confirm
the integrity and expected size of the isolated exosomes. Centrifugations were done at
10 °C using a Beckman Optima X100 ultracentrifuge with a Beckman 50.4Ti or
70.1Ti rotor. Exosome protein content was determined by DC protein assay kit.
Particle content was determined by measuring 1 µl of exosome aliquot diluted in 1ml
PBS with an NTA (NanoSight; Malvern) equipped with a blue laser (405 nm).
Orthotopic GBM models, bioluminescence imaging, and in vivo treatment.
U251 sgCtrl and BTRC-MGMT cells were stably transduced with the HSV1-tk/
GFP/firefly luciferase (TGL) triple-reporter construct and GFP positive cells were
purified by FACS. Four to five weeks old immunodeficient nu/nu mice were then
intracranially injected with the sorted cells (5 × 105 cells) using a stereotactic
apparatus (Stoelting). After intracranial injection, mice were imaged every week to
follow tumor growth and drug response. Mice were anesthetized with 3% isoflurane
before retro-orbital injection with d-luciferin (150 mg/Kg) (Perkin Elmer S.L., Cat.
122796) and imaged with an IVIS Xenogen machine (Caliper Life Sciences). Bio-
luminescence analysis was performed using Living Image software, version 3.
Beginning the day in which tumors were clearly visible by IVIS, mice were ran-
domized into two groups, and temozolomide (50 mg/Kg) or vehicle (DMSO) was
administered intraperitoneally daily for 5 days. For survival curve, mice were then
checked until they developed symptoms of disease (lethargy, weight loss, macro-
cephaly). For IHC analysis, BrdU (150 µg) (Sigma-Aldrich, Cat. B9285) was
administrated intraperitoneally to mice, and mice were then sacrificed 2 h later. For
the h543 orthotopic model, 3 × 105 sgCtrl and SAR1A-MGMT were transplanted
intracranially, and after 1 week mice were randomized in two groups, and temo-
zolomide (100 mg/Kg) or vehicle (DMSO) was administered intraperitoneally daily
for 5 days.
Mice were housed at 22 °C with a 12-h light/ 12-h dark cycle, in the specific
pathogen-free animal house of the Spanish National Cancer Centre under
conditions in accordance with the recommendations of the Federation of European
Laboratory Animal Science Associations (FELASA). All animal experiments were
approved by the Ethical Committee (CEIyBA) and performed in accordance with
the guidelines stated in the International Guiding Principles for Biomedical
Research Involving Animals, developed by the Council for International
Organizations of Medical Sciences (CIOMS).
Statistics and reproducibility. Data in bar graphs are presented as mean and SD,
except otherwise indicated. Results were analyzed by unpaired two-tailed Student’s
t tests or Wilcoxon rank-sum test using the R programming language (version 3.5.3).
Kaplan–Meier survival curves were produced either with GraphPad Prism 6 (Fig. 4a)
or with the “survival” 2.44–1.1 and “survminer” 0.4.6 R packages (Supplementary
Figs. 1e, f and 7g); P-values were generated using the log-rank statistic. Heatmap,
boxplots, and barplots were made with the “ComplexHeatmap” 1.2.0, “ggplot2” 3.2.1
and “ggpubr” 0.2.5R packages, respectively. Each experiment was repeated indepen-
dently (minimum n= 2), unless specifically indicated, with similar results.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The raw sequencing data of the newly sequenced samples are deposited in the European
Genome-phenome Archive (EGA) (https://ega-archive.org/), accession study ID:
EGAS00001004544, and in the Genome Sequence Archive (GSA) of the Beijing Institute
of Genomics (BIG) Data Center Chinese Academy of Sciences (https://bigd.big.ac.cn),
accession number BioProject ID: PRJCA001580. Data from SMC were available in EGA,
accession study ID: EGAS00001001800. Data from TCGA were downloaded from NCI
Genomics Data Commons (GDC) data portal (https://portal.gdc.cancer.gov). Previously
published CGGA data were available at the GSA BIG (https://bigd.big.ac.cn) under
accession number BioProject ID: PRJCA001746 and PRJCA001747. The reference
human genome hg19 is downloaded from http://hgdownload.cse.ucsc.edu/goldenpath/
hg19/bigZips/hg19.fa.gz, while the genome annotation file is downloaded from ftp://ftp.
ensembl.org/pub/release-75/gtf/homo_sapiens/Homo_sapiens.GRCh37.75.gtf.gz. All the
other data supporting the findings of this study are available within the article and its
information files and from the corresponding author upon reasonable request. Source
data are provided with this paper.
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